GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (OTCPK:WXIBF) » Definitions » Cash Conversion Cycle

WXIBF (WuXi Biologics (Cayman)) Cash Conversion Cycle : 157.65 (As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

WuXi Biologics (Cayman)'s Days Sales Outstanding for the six months ended in Jun. 2024 was 122.09.
WuXi Biologics (Cayman)'s Days Inventory for the six months ended in Jun. 2024 was 65.62.
WuXi Biologics (Cayman)'s Days Payable for the six months ended in Jun. 2024 was 30.06.
Therefore, WuXi Biologics (Cayman)'s Cash Conversion Cycle (CCC) for the six months ended in Jun. 2024 was 157.65.


WuXi Biologics (Cayman) Cash Conversion Cycle Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Cash Conversion Cycle Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 114.01 154.09 145.71 153.21 155.49

WuXi Biologics (Cayman) Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 164.85 168.01 157.52 152.25 157.65

Competitive Comparison of WuXi Biologics (Cayman)'s Cash Conversion Cycle

For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WuXi Biologics (Cayman)'s Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where WuXi Biologics (Cayman)'s Cash Conversion Cycle falls into.



WuXi Biologics (Cayman) Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

WuXi Biologics (Cayman)'s Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=111.6+73.34-29.45
=155.49

WuXi Biologics (Cayman)'s Cash Conversion Cycle for the quarter that ended in Jun. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=122.09+65.62-30.06
=157.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


WuXi Biologics (Cayman)  (OTCPK:WXIBF) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


WuXi Biologics (Cayman) Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


WuXi Biologics (Cayman) Business Description

Traded in Other Exchanges
Address
No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 17 billion. North America represented 47.4% of total revenue in 2023. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.